Literature DB >> 9682360

Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli.

G Douce1, M M Giuliani, V Giannelli, M G Pizza, R Rappuoli, G Dougan.   

Abstract

Using a fixed dose of antigen, the immune response to detoxified mutants of LT-WT following intranasal (i.n.), subcutaneous (s.c.) and oral (i.g.) immunisation has been studied. When given i.n., both LT-WT and mutant toxin, K63, generated significant levels of toxin-specific IgG in the serum, and the levels of IgA in nasal and lung lavages were greater than those induced by rLT-B. In comparison, i.g. immunisation of mice with a similar quantity of either LT-WT or K63 toxin induced barely detectable levels of IgG in the sera. However, if the amount of protein used for i.g. immunisation was increased tenfold, relatively good levels of toxin-specific IgG were induced in the sera by both LT-WT or K63. Low levels of toxin-specific IgA were also observed in intestinal washes from these mice. Western blotting of the sera, using the native toxin as an antigen, demonstrated the presence of both anti-A and anti-B subunit antibodies. Most significantly, toxin-neutralising antibodies were induced in the serum, with the strongest activity being induced by the LT-WT, an intermediate activity induced by mutant K63 and a lower response by rLT-B. Together, these data show that ADP-ribosyltransferase is not necessary for mucosal immunogenicity of these proteins, and that the i.n. route of immunisation is more effective than the i.g. route of immunisation for the generation of both systemic (IgG) and mucosal (IgA) immune responses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9682360     DOI: 10.1016/s0264-410x(98)80100-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Refocusing of B-cell responses following a single amino acid substitution in an antigen.

Authors:  M D Chiesa; P M Martensen; C Simmons; N Porakishvili; J Justesen; G Dougan; I M Roitt; P J Delves; T Lund
Journal:  Immunology       Date:  2001-06       Impact factor: 7.397

2.  Mucosal immunogenicity of plant lectins in mice.

Authors:  E C Lavelle; G Grant; A Pusztai; U Pfüller; D T O'Hagan
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

3.  Bacterial ghosts as an oral vaccine: a single dose of Escherichia coli O157:H7 bacterial ghosts protects mice against lethal challenge.

Authors:  Ulrike Beate Mayr; Christoph Haller; Wolfgang Haidinger; Alena Atrasheuskaya; Eugenij Bukin; Werner Lubitz; Georgy Ignatyev
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

4.  Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization.

Authors:  Aziz Alami Chentoufi; Gargi Dasgupta; Anthony B Nesburn; Ilham Bettahi; Nicholas R Binder; Zareen S Choudhury; Winston D Chamberlain; Steven L Wechsler; Lbachir BenMohamed
Journal:  Clin Vaccine Immunol       Date:  2010-01-20

Review 5.  Immunology of gut mucosal vaccines.

Authors:  Marcela F Pasetti; Jakub K Simon; Marcelo B Sztein; Myron M Levine
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 6.  Progress towards a needle-free hepatitis B vaccine.

Authors:  Filipa Lebre; Gerrit Borchard; Maria Conceição Pedroso de Lima; Olga Borges
Journal:  Pharm Res       Date:  2010-11-19       Impact factor: 4.200

7.  Oral and nasal sensitization promote distinct immune responses and lung reactivity in a mouse model of peanut allergy.

Authors:  Romy Fischer; Jerry R McGhee; Huong Lan Vu; T Prescott Atkinson; Raymond J Jackson; Daniel Tomé; Prosper N Boyaka
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

8.  Construction and characterization of bivalent Shigella flexneri 2a vaccine strains SC608(pCFAI) and SC608(pCFAI/LTB) that express antigens from enterotoxigenic Escherichia coli.

Authors:  Ryan T Ranallo; C Piyumi Fonseka; Fred Cassels; Jay Srinivasan; Malabi M Venkatesan
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

9.  Mucosal immunogenicity and adjuvant activity of the recombinant A subunit of the Escherichia coli heat-labile enterotoxin.

Authors:  L De Haan; M Holtrop; W R Verweij; E Agsteribbe; J Wilschut
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

10.  Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants.

Authors:  G Douce; V Giannelli; M Pizza; D Lewis; P Everest; R Rappuoli; G Dougan
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.